INS and cancer: A meta-analysis of all cancer deaths in non-diabetics reported that fasting serum insulin was associated with increased mortality (HR 1.92) in men [58] and the French TELECOM study reported that elevated fasting insulin posed increased risk of cancer death (HR 2.30) in men over a 28-year follow-up [59].